Heidi Ko, Medical Director, Medical Affairs at Labcorp Drug Development, shared on LinkedIn:
“A great day at MBCC 2026 focused on ESR1 mutations, the evolving role of oral SERDs, and the growing clinical impact of ctDNA MRD testing in breast cancer.
It’s exciting to see how rapidly the science is translating into more precise treatment strategies BCSM.
Just as meaningful were the conversations with old and new friends, all committed to improving access to high-quality testing and effective therapies for patients.”
Other articles about Breast Cancer on OncoDaily.
